| Literature DB >> 27610144 |
Preeti Upadhayay1, Manish Kumar1, Kamla Pathak1.
Abstract
In order to achieve prolong corneal contact time of norfloxacin (Entities:
Keywords: Corneal toxicity; Factorial design; Nanoparticulate in-situ gel; Norfloxacin; Ocular irritancy
Year: 2016 PMID: 27610144 PMCID: PMC4986130
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Full factorial experimental design layout
|
|
|
|
|
|
|---|---|---|---|---|
|
|
| |||
| N1 | 0.1 | 0.1 (-1) | 0.05 (-1) | |
| N2 | 0.1 | 0.1(-1) | 0.075 (0) | |
| N3 | 0.1 | 0.1 (-1) | 0.1 (+1) | Y1= % cumulative drug release |
| N4 | 0.1 | 0.15 (0) | 0.05 (-1) | Y2= % entrapment efficiency |
| N5 | 0.1 | 0.15(0) | 0.075 (0) | Y3= % entrapment efficiency |
| N6 | 0.1 | 0.15(0) | 0.1(+1) | |
| N7 | 0.1 | 0.2 (+1) | 0.05 (-1) | |
| N8 | 0.1 | 0.2 (+1) | 0.075(0) | |
| N9 | 0.1 | 0.2 (+1) | 0.1 (+1) | |
| N10 | 0.1 | 0.125 (-0.5) | 0.63 (-0.5) |
Extra design check point formulation
Composition of nanoparticulate in-situ gel of norfloxacin
|
|
|
|
|
|
|---|---|---|---|---|
| N4G1 | 0.3 | 0.15 | 0.05 | 0.1 |
| N4G2 | 0.3 | 0.15 | 0.05 | 0.2 |
| N4G3 | 0.3 | 0.15 | 0.05 | 0.3 |
| N4G4 | 0.3 | 0.15 | 0.05 | 0.4 |
| N4G5 | 0.3 | 0.15 | 0.05 | 0.5 |
Figure 1Mucoadhesive force measuring assembly: (A) balance;(B) left pan;(C) right pan;(D) height adjusting pan; (E) water bath; (F) sample holder; (G) corneal tissue; (H) beaker; (I) burette
Figure 2Phase diagram for preliminary trials for determination of chitosan and TPP concentration.
Evaluation characteristics of norfloxacin nanoparticles
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| N1 | 158.4 | 0.270 | +38 | 6.04 ±0.02 | 64.77 ± 0.37 | 46.35±1.09 | 94.49 ± 0.69 | |
| N2 | 192.8 | 0.324 | +31 | 6.09± 0.01 | 68.27 ± 0.18 | 43.81±0.74 | 91.37 ± 0.50 | |
| N3 | 345.8 | 0.470 | +28 | 5.92 ±0.03 | 68.95 ± 0.49 | 32.34±0.60 | 82.61. ± 0.87 | |
| N4 | 164.2 | 0.071 | +32 | 5.85 ±0.01 | 74.51 ± 0.33 | 45.37±1.27 | 95.74 ± 0.92 | |
| N5 | 215.6 | 0.120 | +42 | 5.94± 0.03 | 76.42 ± .21 | 42.24±1.27 | 93.11 ± 0.36 | |
| N6 | 243.8 | 0.181 | +39 | 6.1 ± 0.02 | 77.38 ± 0.29 | 37.65±0.67 | 90.30 ± 0.43 | |
| N7 | 256.1 | 0.210 | +46 | 6.05± 0.02 | 70.17 ± 0.46 | 38.80±1.21 | 92.18 ± 0.19 | |
| N8 | 298.4 | 0.180 | +41 | 6.18 ±0.03 | 71.88 ± 0.87 | 36.75±0.89 | 89.63 ± 0.36 | |
| N9 | 310.6 | 0.235 | +39 | 6.21± 0.13 | 73.21 ± 0.26 | 33.31±0.40 | 86.54 ± 1.52 | |
| N10 | 164.6 | 0.112 | +37 | 6.13 ±0.11 | 72.65 ±0.87 | 40.55±0.68 | 91.23 ± 1.48 | |
Extra design check point
Figure 3In-vitro release profiles of nanoparticles N1-N10.
Kinetic modeling data of norfloxacin nanoparticulate formulations (N1-N9
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||
| R2 | n | ||||||||
| N1 | 0.911 | 0.638 | 0.994 | 0.981 | 0.981 | 0.965 | 0.984 | 0.589 | |
| N2 | 0.972 | 0.694 | 0.955 | 0.981 | 0.988 | 0.96 | 0.976 | 0.495 | |
| N3 | 0.939 | 0.674 | 0.994 | 0.983 | 0.948 | 0.978 | 0.994 | 0.565 | |
| N4 | 0.906 | 0.636 | 0.994 | 0.948 | 0.902 | 0.993 | 0.998 | 0.566 | |
| N5 | 0.883 | 0.632 | 0.986 | 0.965 | 0.945 | 0.968 | 0.988 | 0.550 | |
| N6 | 0.896 | 0.639 | 0.997 | 0.965 | 0.912 | 0.972 | 0.978 | 0.507 | |
| N7 | 0.934 | 0.65 | 0.989 | 0.955 | 0.894 | 0.980 | 0.982 | 0.511 | |
| N8 | 0.933 | 0.653 | 0.982 | 0.973 | 0.932 | 0.986 | 0.997 | 0.502 | |
| N9 | 0.949 | 0.675 | 0.977 | 0.982 | 0.947 | 0.974 | 0.991 | 0.521 | |
Tabulated statistical evaluation of the responses and validation of experimental design
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||
|
|
|
|
|
|
| |||||||
| X1 | -0.020 | 0.0133 | 2.21 | 0.0013 | 0.13 | 0.0508 | ||||||
| X2 | -38.3 | 0.9756 | 1.68 | 0.0016 | 0.23 | 0.0128 | ||||||
| X1X2 | 1.56 | 0.0034 | -0.29 | 0.0036 | -0.15 | 0.0673 | ||||||
| X12 | -.358 | 0.1064 | -6.56 | 0.3303 | 0.20 | 0.0716 | ||||||
| X22 | -1.06 | 0.0281 | -0.69 | 0.0003 | 0.21 | 0.7957 | ||||||
|
| ||||||||||||
|
|
|
|
|
|
| |||||||
| Y1 | 13.65 | 0.0133 | 0.9317 | 11.406 | 1.66 | |||||||
| Y2 | 110.56 | 0.0013 | 0.9946 | 30.934 | 0.69 | |||||||
| Y3 | 10.80 | 0.0391 | 0.9474 | 8.786 | 1.92 | |||||||
|
| ||||||||||||
|
|
|
|
|
|
| |||||||
| Particle size (nm) | 167.03 | 164.6 | 1.823 | Particle size (nm) | 167.03 | |||||||
| % Entrapment efficiency | 74.38 | 72.65 | 2.381 | % Entrapment efficiency | 74.38 | |||||||
| % CDR after 12 hrs | 91.39 | 91.23 | 0.175 | % CDR after 12 hrs | 91.39 | |||||||
Figure 4Diffuse reflectance spectra: (a) Nanoparticles N4, (b) Norfloxacin, (c) Chitosan, (d) Physical mixture
Figure 53 D Response surface plots showing combined effect of chitosan and TPP on (a) % cumulative drug release, (b) % entrapment efficiency, (c) Particle size, (d) Desirability of formulation
Evaluation characteristics of nanoparticulate in-situ gels of norfloxacin
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| N4G1 | Transparent | 91.88 ± 0.80 | 6.25 ± 0.86 | 99.24 ± 2.38 | - |
| N4G2 | Transparent | 92.20 ± 0.72 | 6.17 ± 0.41 | 96.88 ± 1.63 | + |
| N4G3 | Transparent | 94.36 ± 0.66 | 6.02 ± 0.53 | 98.74 ± 1.18 | ++ |
| N4G4 | Transparent | 95.66 ± 0.57 | 5.96 ± 0.58 | 97.38 ± 2.35 | ++ |
| N4G5 | Transparent | 96.33 ± 0.57 | 5.84 ± 0.63 | 98.31 ± 1.39 | +++ |
Figure 63D Response surface plots showing combined effect of chitosan and TPP on (a) % cumulative drug release, (b) % entrapment efficiency, (c) Particle size, (d) Desirability of formulation
Figure 7Comparative ex vivo transcorneal permeation profiles of nanoparticulate in-situ gel (N4G5) and marketed formulation
Figure 8TEM images (a) Optimized nanoparticulate in-situ gel (N4G5), (b) Optimized nanoparticles N4.
Figure 9Histological cross section of excised goat cornea, stained with haematoxylin-eosin after incubation in (a) Normal saline (control); (b) N4G5; (c) isopropyl alcohol (positive control
Figure 10Bar chart showing zone of inhibition for nanoparticulate in-situ gel (N4G5) and marketed formulation
Scoring of HET-CAM test of N4G5 in-situ nanoparticulate gel of norfloxacin conducted on fertile eggs
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
|
|
|
|
|
|
| ||
| 0.9% NaCl (-ve control) | Egg 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Egg 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Egg 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Mean | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Optimized formulations | Egg 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Egg 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Egg 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Mean | 0 | 0 | 0 | 0 | 0 | 0 | 0.33 | |
| 0.1 M NaOH | Egg 1 | 1 | 3 | 3 | 3 | 3 | 3 | 3 |
| Egg 2 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Egg 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Mean | 1.88 | 3 | 3 | 3 | 3 | 3 | 3 | |
0= Non irritant (No visible haemorrhage); 1= Mild irritant (Just visible membrane discoloration); 2= moderately irritant (Structures are covered partially due to membrane discolouration or haemorrhage); 3= severely irritant(Structures are covered totally due to membrane discoloration or haemorrhage).
Figure 11Images of HET-CAM test of N4G5 in-situ nanoparticulate gel of norfloxacin conducted on fertile eggs.